{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T04:14:56Z","timestamp":1771992896572,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,4,2]],"date-time":"2020-04-02T00:00:00Z","timestamp":1585785600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,4,2]],"date-time":"2020-04-02T00:00:00Z","timestamp":1585785600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologe"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1007\/s00120-020-01174-0","type":"journal-article","created":{"date-parts":[[2020,4,2]],"date-time":"2020-04-02T14:02:36Z","timestamp":1585836156000},"page":"550-558","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Leitliniengerechte Therapie von Harnwegsinfektionen","Guideline-based treatment of urinary tract infections"],"prefix":"10.1007","volume":"59","author":[{"given":"B.","family":"Ternes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F. M. E.","family":"Wagenlehner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,4,2]]},"reference":[{"key":"1174_CR1","unstructured":"Leitlinienprogramm DGU Interdisziplin\u00e4re S3 Leitlinie: Epidemiologie, Diagnostik, Therapie, Pr\u00e4vention und Management unkomplizierter, bakterieller, ambulant erworbener Harnwegsinfektionen bei erwachsenen Patienten. Langversion 1.1\u20132, 2017 AWMF Registernummer: 043\/044. https:\/\/www.awmf.org\/uploads\/tx_szleitlinien\/043-044l_S3_Harnwegsinfektionen_2017-05.pdf. Zugegriffen: 9. Jan. 2020"},{"key":"1174_CR2","isbn-type":"print","volume-title":"EAU Guidelines on Urological Infections Edn. presented at the EAU Annual Congress Barcelona 2019","author":"European Association of Urology","year":"2020","unstructured":"European Association of Urology (2020) EAU Guidelines on Urological Infections Edn. presented at the EAU Annual Congress Barcelona 2019. ISBN 978-94-92671-04\u20112","ISBN":"https:\/\/id.crossref.org\/isbn\/9789492671042"},{"key":"1174_CR3","unstructured":"Paul-Ehrlich Gesellschaft S2k-Leitlinie: Kalkulierte parenterale Initialtherapie bakterieller Erkrankungen bei Erwachsenen \u2013 Update 2018. 2. aktualisierte Version, erstellt am 25. Juli 2019. AWMF-Registernummer 082-006. https:\/\/www.awmf.org\/uploads\/tx_szleitlinien\/082-006l_S2k_Parenterale_Antibiotika_2019-08.pdf. Zugegriffen: 9. Jan. 2020"},{"key":"1174_CR4","doi-asserted-by":"publisher","DOI":"10.1177\/1756287219832172","author":"M Medina","year":"2019","unstructured":"Medina\u00a0M, Castillo-Pino\u00a0E (2019) An introduction to the epidemiology and burden of urinary tract infections. Ther Adv Urol. https:\/\/doi.org\/10.1177\/1756287219832172","journal-title":"Ther Adv Urol"},{"key":"1174_CR5","unstructured":"Philipps Universit\u00e4t Marburg, Universit\u00e4t Giesen (2020) https:\/\/www.ukgm.de\/ugm_2\/deu\/ugi_uro\/PDF\/DeutschACSSFragebogen.pdf. Zugegriffen: 9. Jan. 2020"},{"key":"1174_CR6","unstructured":"ACSS (Hrsg) (2020) http:\/\/www.acss.world\/cystitis.html. Zugegriffen: 9. Jan. 2020"},{"issue":"5","key":"1174_CR7","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/j.eururo.2008.05.010","volume":"54","author":"KG Naber","year":"2008","unstructured":"Naber\u00a0KG, Schito\u00a0G, Botto\u00a0H, Palou\u00a0J, Mazzei\u00a0T (2008) Surveillance study in Europe and Brazil on clinical aspects and Antimicrobial Resistance Epidemiology in Females with Cystitis (ARESC): implications for empiric therapy. Eur Urol 54(5):1164\u20131175. https:\/\/doi.org\/10.1016\/j.eururo.2008.05.010","journal-title":"Eur Urol"},{"issue":"4","key":"1174_CR8","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1080\/00365540410019642","volume":"36","author":"SA Ferry","year":"2004","unstructured":"Ferry\u00a0SA, Stig\u00a0EH, Stenlund\u00a0H, Lundholm\u00a0R, Monsen\u00a0TJ (2004) The natural course of uncomplicated lower urinary tract infection in women illustrated by a\u00a0randomized placebo controlled study. Scand J Infect Dis 36(4):296\u2013301. https:\/\/doi.org\/10.1080\/00365540410019642","journal-title":"Scand J Infect Dis"},{"issue":"482","key":"1174_CR9","first-page":"729","volume":"52","author":"TCM Christiaens","year":"2002","unstructured":"Christiaens\u00a0TCM, De Meyere\u00a0M, Verschraegen\u00a0G, Peersman\u00a0W, Heytens\u00a0S, De Maeseneer\u00a0JM (2002) Randomised controlled trial of nitrofurantoin versus placebo in the treatment of uncomplicated urinary tract infection in adult women. Br J Gen Pract 52(482):729\u2013734","journal-title":"Br J Gen Pract"},{"issue":"4","key":"1174_CR10","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1086\/520427","volume":"29","author":"JW Warren","year":"1999","unstructured":"Warren\u00a0JW, Abrutyn\u00a0E, Hebel\u00a0JR, Johnson\u00a0JR, Schaeffer\u00a0AJ, Stamm\u00a0WE (1999) Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Clin Infect Dis 29(4):745\u2013759. https:\/\/doi.org\/10.1086\/520427","journal-title":"Clin Infect Dis"},{"issue":"11","key":"1174_CR11","doi-asserted-by":"publisher","first-page":"175","DOI":"10.3238\/arztebl.2009.0175","volume":"106","author":"FME Wagenlehner","year":"2009","unstructured":"Wagenlehner\u00a0FME, Naber\u00a0KG, Bschleipfer\u00a0T, Br\u00e4hler\u00a0E, Weidner\u00a0W (2009) Prostatitis and male pelvic pain syndrome: diagnosis and treatment. Dtsch Arztebl Int 106(11):175\u2013183. https:\/\/doi.org\/10.3238\/arztebl.2009.0175","journal-title":"Dtsch Arztebl Int"},{"key":"1174_CR12","unstructured":"Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte (BfArM) (Hrsg) (2020) https:\/\/www.bfarm.de\/SharedDocs\/Risikoinformationen\/Pharmakovigilanz\/DE\/RHB\/2019\/rhb-fluorchinolone.pdf;jsessionid=D416E1E4D57212010F2AAB6AA1D519BC.1_cid329?__blob=publicationFile&v=4. Zugegriffen: 9. Jan. 2020"},{"issue":"4","key":"1174_CR13","doi-asserted-by":"publisher","first-page":"583","DOI":"10.2165\/00003495-199753040-00004","volume":"53","author":"LE Nicolle","year":"1997","unstructured":"Nicolle\u00a0LE (1997) A Practical Guide to the Management of Complicated Urinary Tract Infection. Drugs 53(4):583\u2013592. https:\/\/doi.org\/10.2165\/00003495-199753040-00004","journal-title":"Drugs"},{"key":"#cr-split#-1174_CR14.1","unstructured":"Weis S, Dickmann P, Pletz MW, Coldewey SM, Gerlach H, Bauer M (2017) Sepsis 2017: Eine neue Definition f\u00fchrt zu neuen Konzepten. Dtsch Arztebl 2017"},{"key":"#cr-split#-1174_CR14.2","unstructured":"114(29-30). https:\/\/www.aerzteblatt.de\/archiv\/192597\/Sepsis-2017-Eine-neue-Definition-fuehrt-zu-neuen-Konzepten. Zugegriffen: 24. Jan. 2020"},{"key":"1174_CR15","unstructured":"Gemeinsamer Bundesausschusses (2019) Richtlinien \u00fcber die \u00e4rztliche Betreuung w\u00e4hrend der Schwangerschaft und nach der Entbindung (\u201eMutterschafts-Richtlinien\u201c). https:\/\/www.g-ba.de\/downloads\/39-261-3740\/2019-03-22_Mu-RL_Screening-asympt-Bakteriurie_BAnz.pdf. Zugegriffen: 15. Jan. 2020"},{"key":"1174_CR16","unstructured":"BfArM Risikobewertungsverfahren (02.05.2019): Fluorchinolone: Schwere und langanhaltende Nebenwirkungen im Bereich Muskeln, Gelenke und Nervensystem. https:\/\/www.bfarm.de\/SharedDocs\/Risikoinformationen\/Pharmakovigilanz\/DE\/RV_STP\/a-f\/fluorchinolone-bewegungsapparat.html. Zugegriffen: 24. Jan. 2020"},{"key":"1174_CR17","doi-asserted-by":"publisher","DOI":"10.1159\/000493368","author":"Wagenlehner","year":"2018","unstructured":"Wagenlehner, Abramov-Sommariva, H\u00f6ller, Steindl, Naber (2018) Non-antibiotic herbal therapy (BNO 1045) versus antibiotic therapy (Fosfomycin Trometamol) for the treatment of acute lower uncomplicated urinary tract infections in women: a double-blind, parallel-group, randomized, Multicentre, non-inferiority phase III trial. Urol Int. https:\/\/doi.org\/10.1159\/000493368","journal-title":"Urol Int"},{"issue":"2014","key":"1174_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.idc.2013.09.003","volume":"28","author":"Foxman","year":"2014","unstructured":"Foxman (2014) Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden. Infect Dis Clin North Am 28(2014):1\u201313. https:\/\/doi.org\/10.1016\/j.idc.2013.09.003","journal-title":"Infect. Dis. Clin. North Am."},{"key":"1174_CR19","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/1471-2393-12-52","volume":"12","author":"Kazemier","year":"2012","unstructured":"Kazemier, Schneeberger, De Miranda et\u00a0al (2012) Costs and effects of screening and treating low risk women with a\u00a0singleton pregnancy for asymptomatic bacteriuria, the ASB study. BMC Pregnancy Childbirth 12:52. https:\/\/doi.org\/10.1186\/1471-2393-12-52","journal-title":"BMC Pregnancy Childbirth"},{"issue":"1","key":"1174_CR20","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/s0002-9343(02)01054-9","volume":"113","author":"Foxman","year":"2002","unstructured":"Foxman (2002) Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Am J Med 113(1):5\u201313. https:\/\/doi.org\/10.1016\/s0002-9343(02)01054-9","journal-title":"Am J Med"},{"key":"1174_CR21","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1097\/JU.0000000000000296","volume":"202","author":"J Anger","year":"2019","unstructured":"Anger\u00a0J, Lee\u00a0U, Ackerman\u00a0AL et\u00a0al (2019) Recurrent uncomplicated urinary tract infections in women: aUA\/CUA\/SUFU guideline. J\u00a0Urol 202:282\u2013289","journal-title":"J Urol"},{"key":"1174_CR22","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1055\/a-0976-8677","volume":"50","author":"W Lorenz","year":"2019","unstructured":"Lorenz\u00a0W (2019) Referiert und kommentiert, Rezidivierender Harnwegsinfekt der Frau: Diagnose, Therapie, Pr\u00e4vention. Aktuelle Urol 50:468\u2013472. https:\/\/doi.org\/10.1055\/a-0976-8677","journal-title":"Aktuelle Urol"},{"issue":"10","key":"1174_CR23","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1093\/cid\/ciz021","volume":"68","author":"Nicolle","year":"2019","unstructured":"Nicolle, Gupta, Bradley, Colgan, DeMuri, Drekonja, Eckert, Geerlings, K\u00f6ves, Hooton, Juthani-Mehta, Knight, Saint, Schaeffer, Trautner, Wullt, Siemieniuk (2019) Clinical practice guideline for the management of asymptomatic bacteriuria: 2019 update by the infectious diseases society of America. Clin Infect Dis 68(10):1611\u20131615. https:\/\/doi.org\/10.1093\/cid\/ciz021","journal-title":"Clin Infect Dis"},{"issue":"6","key":"1174_CR24","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.eururo.2017.07.014","volume":"72","author":"B K\u00f6ves","year":"2017","unstructured":"K\u00f6ves\u00a0B et al (2017) Benefits and harms of treatment of asymptomatic bacteriuria: a systematic review and meta-analysis by the European Association of Urology urological infection guidelines panel. Eur Urol 72(6):865\u2013868. https:\/\/doi.org\/10.1016\/j.eururo.2017.07.014","journal-title":"Eur Urol"},{"issue":"11","key":"1174_CR25","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1016\/S1473-3099(15)00070-5","volume":"15","author":"Kazemier","year":"2015","unstructured":"Kazemier, Koningstein, Schneeberger, Ott, Bossuyt, de Miranda, Vogelvang, Verhoeven, Langenveld, Woiski, Oudijk, van der Ven, Vlegels, Kuiper, Feiertag, Pajkrt, de Groot, Mol, Geerlings (2015) Maternal and neonatal consequences of treated and untreated asymptomatic bacteriuria in pregnancy: a\u00a0prospective cohort study with an embedded randomised controlled trial. Lancet Infect Dis 15(11):1324\u20131333. https:\/\/doi.org\/10.1016\/S1473-3099(15)00070-5","journal-title":"Lancet Infect Dis"},{"key":"1174_CR26","doi-asserted-by":"publisher","first-page":"h6544","DOI":"10.1136\/bmj.h6544","volume":"351","author":"I G\u00e1gyor","year":"2015","unstructured":"G\u00e1gyor\u00a0I, Bleidorn\u00a0J, Kochen\u00a0MM, Schmiemann\u00a0G, Wegscheider\u00a0K, Hummers-Pradier\u00a0E (2015) Ibuprofen versus fosfomycin for uncomplicated urinary tract infection in women: randomised controlled trial. BMJ 351:h6544. https:\/\/doi.org\/10.1136\/bmj.h6544","journal-title":"BMJ"},{"key":"1174_CR27","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1007\/s00120-015-3873-5","volume":"54","author":"J Alidjanov","year":"2015","unstructured":"Alidjanov\u00a0J, Pilatz\u00a0A, Abdufattaev\u00a0U et\u00a0al (2015) Deutsche Validierung des \u201eAcute Cystitis Symptom Score\u201c. Urologe 54:1269\u20131276. https:\/\/doi.org\/10.1007\/s00120-015-3873-5","journal-title":"Urologe"},{"issue":"Suppl","key":"1174_CR28","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.ijantimicag.2011.09.009","volume":"38","author":"TE Johansen","year":"2011","unstructured":"Johansen\u00a0TE, Botto\u00a0H, Cek\u00a0M, Grabe\u00a0M, Tenke\u00a0P, Wagenlehner\u00a0FM, Naber\u00a0KG (2011) Critical review of current definitions of urinary tract infections and proposal of an EAU\/ESIU classification system. Int J Antimicrob Agents 38(Suppl):64\u201370. https:\/\/doi.org\/10.1016\/j.ijantimicag.2011.09.009","journal-title":"Int J Antimicrob Agents"},{"key":"1174_CR29","unstructured":"https:\/\/www.ukgm.de\/ugm_2\/deu\/ugi_uro\/PDF\/DeutschACSSFragebogen.pdf. Zugegriffen: 25. Jan. 2020"}],"container-title":["Der Urologe"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-020-01174-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00120-020-01174-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-020-01174-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T23:19:51Z","timestamp":1617319191000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00120-020-01174-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,2]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["1174"],"URL":"https:\/\/doi.org\/10.1007\/s00120-020-01174-0","relation":{},"ISSN":["0340-2592","1433-0563"],"issn-type":[{"value":"0340-2592","type":"print"},{"value":"1433-0563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,2]]},"assertion":[{"value":"2 April 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"B.\u00a0Ternes gibt an, dass kein Interessenkonflikt besteht. F.M.E.\u00a0Wagenlehner: Achaogen, Astellas, AstraZeneca, Bionorica, Enteris BioPharma, GSK, Helperby Therapeutics, Janssen, Klosterfrau, LeoPharma, MerLion, MSD, OM Pharma\/Vifor Pharma, Paratek, Pfizer, RosenPharma, Shionogi, VenatoRx.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}